Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
AME-133v is a humanized monoclonal antibody engineered to have increased affinity to CD20 and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) better than rituximab. Safety, pharmacokinetics, and efficacy were assessed in a phase 1/2 trial in patients with previously treated follicular lymphoma (FL).
Pharmacology, Toxicology and Pharmaceutical Science
2
4%
Immunology and Microbiology
2
4%
Other
7
13%
Unknown
9
17%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 September 2026.
All research outputs
#2,913,430
of 33,695,692 outputs
Outputs from Clinical Cancer Research
#2,499
of 17,421 outputs
Outputs of similar age
#15,314
of 199,844 outputs
Outputs of similar age from Clinical Cancer Research
#19
of 138 outputs
Altmetric has tracked 33,695,692 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,844 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 138 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.
